Clinical Research

Government-funded program wants better AI for managing heart failure in the US
The long-term goal is to bring 24-7 cardiac care to every American, even those living in counties with no cardiologists.
Acoramidis bests tafamidis in head-to-head comparison of ATTR-CM drugs
Acoramidis was associated with a 43% lower risk of diuretic intensification and a 34% lower risk of clinical worsening overall.
TAVR timing: Waiting more than 6 months may hurt survival odds
When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
European Society of Cardiology joins effort to improve access to heart data
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
5 practice-changing trials from ESC Congress 2026
Damodhar Suresh, MD, spoke to Cardiovascular Business about some of the biggest studies presented during the annual ESC conference in Munich, Germany.

doctor examines patient data on their tablet

Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?

Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.

When Apple previewed its watchOS 9 update in early June, one of the key features the company highlighted was a new tracking option for atrial fibrillation (AFib) patients. The AFib History feature, approved for patients 22 years and older who have been diagnosed with AFib, was designed to help users gain a better understanding of their symptoms and easily share data with healthcare providers.

Apple Watch AFib feature becomes first-ever digital tool approved by FDA to evaluate medical devices

Healthcare technology companies can now use AFib findings recorded by an Apple Watch to help demonstrate the effectiveness of their devices to the FDA.

Sunil Rao, MD, NYU, explains the DANGER-SHOCK trial at ACC 2024 and how it may help improve cardiogenic shock survival.

Cardiologist Sunil Rao highlights importance of DanGer Shock compared to other cardiogenic shock trials

Sunil Rao, MD, director of interventional cardiology at NYU Langone, says DanGer Shock is a "very, very important study" when it comes to the treatment of cardiogenic shock.

PAD patients face greater risk of death, complications after a heart attack

PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations.

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.